Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Meningitis b vaccine tested as gonorrhea shield in men

NCT ID NCT05766904

Prevention Sponsor: Chinese University of Hong Kong Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 3 trial tests whether a meningitis B vaccine (Bexsero) can prevent gonorrhea infections in men who have sex with men. 150 participants in Hong Kong will receive either the vaccine or a placebo. Researchers will compare infection rates and monitor safety.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
4CMenB vaccine (Bexsero)
What this could lead to
If it works, this could point toward a new way to prevent gonorrhea, a common sexually transmitted infection, using an existing vaccine.
What could go wrong
This is a small, early-stage trial with only 150 men in Hong Kong. The vaccine may not prove effective, and results may not apply to other populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 150 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2023

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 50 years

Sex

Male participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male adult who has had sex with another male in the past six months * Ages 18 years or above * Normally resides in Hong Kong * Able to communicate in written and spoken Chinese or English * At risk of gonorrhoea infection (had condomless sex with more than one man within the last six months, history of STI diagnosis, inclination to have condomless sex, and other PrEP-eligible criteria) * Negative NG test result at the time of recruitment * No history of previous vaccination with MenB vaccines * Able and willing to attend all study visits Exclusion Criteria: * Contraindications to receive MenB vaccine * Unable to give informed consent

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Gonorrhea are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

sexually transmitted disease gonorrhea prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Gonorrhea Sexually transmitted infection

Contacts and locations

Locations

  • Stanley Ho Centre for Emerging Infectious Diseases

    Shatin, Hong Kong

More trials for these conditions

Other studies related to the condition(s) this trial covers.